Multivariate Analyses Indicate That The Cytokine Response To Lymphodepletion May Be Better Associated Than Lymphodepletion Intensity With The Efficacy Of Cd19 Car-T Cell Immunotherapy For Aggressive B-Cell Non-Hodgkin Lymphoma

IntroductionCD19 chimeric antigen receptor (CAR)-T cell therapy has shown efficacy in Non-Hodgkin lymphoma (NHL), but the factors associated with durable remission have not been identified.ObjectivesWe report multivariate analyses of factors impacting progression-free survival (PFS) in NHL patients (pts) treated with cyclophosphamide and fludarabine (Cy/Flu) lymphodepletion (LD) and CD19 CAR-T cells.MethodsWe conducted a phase 1/2 open-label clinical trial (NCT01865617) with the primary objective of evaluating the feasibility and safety of a defined composition of CD19 CAR-T cells after LD in pts with R/R CD19+ B-cell malignancies. PFS was defined as the time from CAR-T cell infusion until disease progression or death. Multivariate models using elastic net were performed for analysis of response and PFS.ResultsCharacteristics of the 57 pts in the study are shown in Tbl 1. Thirty-six (63%) received …